In site-specific analyses, significant correlation seen for poor oral health with hepatocellular carcinoma.
Fibronectin may be a potential marker for hepatitis B surface antigen seroclearance.
Advantage of interferon-based antiviral therapy reached statistical significance at 5-year follow-up.
Certain characteristics and HIV-related factors may help predict whether certain demographics of people with HIV will have an optimal response to reinforced hepatitis B virus vaccination.
In multivariate analysis, age, albumin concentration, T2DM independently tied to progression.
As the roles of nurse practitioners and physician assistants continue to evolve, efforts are being made to integrate a NP/PA model into the hepatology and liver transplant field.
Prevalence of alcoholic fatty liver disease remained relatively unchanged from 2001 to 2016, but alcoholic fatty liver disease with fibrosis stage 2 and 3 or greater increased significantly.
Multiple infection outbreaks among those reporting drug use, homelessness account for most reports.
Facial involves injecting nutrient-rich plasma into the face using a microneedling pen.
An update to the Health Alert Network advisory that was released in June 2018 was issued by the CDC on March 25th.
Investigators sought to categorize hepatitis C virus infections in HIV-positive MSM as either domestically or internationally acquired and evaluate how this classification changed over time.
Sustained virologic response to the HCV in patients with HCV and HIV coinfection is associated with a lowered risk of diabetes and mortality.
Whole grains and possibly cereal fiber, bran appear linked to lower risk for hepatocellular carcinoma.
A team of investigators sought to identify the independent effects of hyperlipidemia and statin exposure on mortality, hepatic decompensation, and hepatocellular carcinoma in individuals with cirrhosis.
Universal healthcare screening at the first clinical encounter of pregnancy was found to be cost-effective and improved health outcomes in women diagnosed with HCV and identification of HCV exposure in neonates.
Topline data from the Phase 3 STELLAR-4 trial showed that selonsertib, an investigational treatment for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), was not associated with a significant improvement in fibrosis without worsening of NASH.
The ACIP and CDC have approved and released 2019 recommendations for the adult immunization schedule in the US.
Women less likely to be treated than men; treatment visit, medication tied to improved 1-year outcomes.
Increased-risk donors significantly more likely to have positive HBV, HCV screening results.
Physical activity was found to be associated with a reduced risk for hepatocellular carcinoma.